Cited by 505Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

Inoue, Akira, Kobayashi, Kunihiko, Usui, Kazuhiro, Maemondo, Makoto, Okinaga, Shoji, Mikami, Iwao, Ando, Masahiro, Yamazaki, Koichi, Saijo, Yasuo, Gemma, Akihiko, Miyazawa, Hitoshi, Tanaka, Tomoaki, Ikebuchi, Kenji, Nukiwa, Toshihiro, Morita, Satoshi, Hagiwara, Koichi·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2008.18.7658

Open this paper in CoChat — free account

Abstract

Purpose This multicenter phase II study was undertaken to investigate the efficacy and feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations without indication for chemotherapy as a result of poor performance status (PS). Patients and Methods Chemotherapy-naïve patients with poor PS (patients 20 to 74 years of age with Eastern Cooperative Oncology Group PS 3 to 4, 75 to 79 years of age with PS 2 to 4, and ≥ 80 years of age with PS 1 to 4) who had EGFR mutations examined by the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method were enrolled and received gefitinib (250 mg/d) alone. Results Between February 2006 and May 2007, 30 patients with NSCLC and poor PS, including 22 patients with PS 3 to 4, were enrolled. The overall response rate was 66% (90% CI, 51% to 80%), and the disease control rate was 90%. PS improvement rate was 79% (P < .00005); in particular, 68% of the 22 patients improved from ≥ PS 3 at baseline to ≤ PS 1. The median progression-free survival, median survival time, and 1-year survival rate were 6.5 months, 17.8 months, and 63%, respectively. No treatment-related deaths were observed. Conclusion This is the first report indicating that EGFR mutation-positive patients with extremely poor PS benefit from first-line gefitinib. Because there previously has been no standard treatment for these patients with short life expectancy other than best supportive care, examination of EGFR mutations as a biomarker is recommended in this patient population.

Integrity signals

Registry

Crossref · 10.1200/jco.2008.18.7658

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W. T., Smith, T. J., Baker, S., Olak, J., Stover, D. E., Strawn, J. R., Turrisi, A. T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,411

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 1

Arteaga CL, ASCO virtual meeting 2004

Sorted by citations

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Self-citation
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
Travis, W. D., Brambilla, E. M., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Schil, P. E. V., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,834
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,430
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Chirieac, L. R., D’Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M. C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,315
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Hendriks, L. E. L., Kerr, K. M., Menis, J., Mok, T. S. K., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.009 · Cited by 926
Cell death-based treatment of lung adenocarcinoma
Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0063-y · Cited by 768
Non–Small Cell Lung Cancer
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 737
Non–Small Cell Lung Cancer
Ettinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A. C., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., Ganti, A. K., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0056 · Cited by 729
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.001 · Cited by 461
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0720-oa · Cited by 426
Overview of current systemic management of EGFR-mutant NSCLC
Hsu, W.-H., Yang, J. C., Mok, T. S. K., & Loong, H. H.-F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx702 · Cited by 394
Non–Small Cell Lung Cancer
Ettinger, D. S., Akerley, W., Borghaei, H., Chang, A. C., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., Ganti, A. K., Govindan, R., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0130 · Cited by 352
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation
Park, S. J., Kim, H. T., Lee, D., Kim, K. P., Kim, S.-W., Suh, C. H., & Lee, J. S. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.05.092 · Cited by 324
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 296
Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
Pirker, R., Herth, F. J. F., Kerr, K. M., Filipits, M., Tarón, M., Gandara, D. R., Hirsch, F. R., Grunenwald, D. H., Popper, H., Smit, E. F., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f1c8de · Cited by 283
Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy
Morris, P. G., Reiner, A. S., Thon, O. R., Clarke, J. L., Panageas, K. S., Perez, H. R., Kris, M. G., Chan, T. A.-T., DeAngelis, L. M., & Omuro, A. M. P. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182398e4f · Cited by 277
Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
Jankú, F., Stewart, D. J., & Kurzrock, R. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.64 · Cited by 258
Molecular pathways and therapeutic targets in lung cancer
Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1891 · Cited by 220
“Data from several clinical trials have indicated that patients with EGFR mutations have improved progression-free survival (PFS) and overall survival (OS) when treated with EGFR inhibitors compared to patients with the same mutations who received standard-of-care, cytotoxic chemotherapy regimens [13-15].”
Background
EGFR-mutated lung cancer: a paradigm of molecular oncology
Zhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S., & Halmos, B. (2010) · Oncotarget · doi:10.18632/oncotarget.186 · Cited by 197
Treatment of Stage IV Non-small Cell Lung Cancer
Socinski, M. A., Evans, T. L., Gettinger, S. N., Hensing, T. A., Sequist, L. V. D., Ireland, B. K., & Stinchcombe, T. E. (2013) · CHEST Journal · doi:10.1378/chest.12-2361 · Cited by 206
Frequency of and variables associated with the EGFR mutation and its subtypes
Tanaka, T., Matsuoka, M., Sutani, A., Gemma, A., Maemondo, M., Inoue, A., Okinaga, S., Nagashima, M., Oizumi, S., Uematsu, K., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24746 · Cited by 183
Self-citation
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
Liao, B.-C., Lee, J., Lin, C., Chen, Y., Chang, C., Ho, C., Shih, J., Yu, C., & Yang, J. C. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000669 · Cited by 184
Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology
Pallis, A. G., Gridelli, C., Wedding, U., Finn, C. F., Veronesi, G., Jaklitsch, M. T., Luciani, A., & O'Brien, M. E. R. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu022 · Cited by 186
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
Takeda, M., Okamoto, I., & Nakagawa, K. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.026 · Cited by 182
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
Lee, S. M., Khan, I., Upadhyay, S., Lewanski, C. R., Falk, S. J., Skailes, G., Marshall, E., Woll, P. J., Hatton, M. Q. F., Lal, R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70412-6 · Cited by 179
Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
Ludovini, V., Bianconi, F., Pistola, L., Chiari, R., Minotti, V., Colella, R., Giuffrida, D., Tofanetti, F. R., Siggillino, A., Flacco, A., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820a3a6b · Cited by 180
Nanotechnology in the diagnosis and treatment of lung cancer
Cryer, A. M., & Thorley, A. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.010 · Cited by 177
MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells
Cao, M., Seike, M., Soeno, C., Mizutani, H., Kitamura, K., Minegishi, Y., Noro, R., Yoshimura, A., Cai, L., & Gemma, A. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1535 · Cited by 171
Self-citation
Targeted therapies for non-small cell lung cancer
Dempke, W. C. M., Sütö, T., & Reck, M. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.10.012 · Cited by 165
Personalized medicine in lung cancer: what we need to know
Mok, T. S. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.126 · Cited by 165
The effect on survival of continuing chemotherapy to near death
Saito, A. M., Landrum, M. B., Neville, B. A., Ayanian, J. Z., & Earle, C. C. (2011) · BMC Palliative Care · doi:10.1186/1472-684x-10-14 · Cited by 157
First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study
Maemondo, M., Minegishi, Y., Inoue, A., Kobayashi, K., Harada, M., Okinaga, S., Morikawa, N., Oizumi, S., Tanaka, T., Isobe, H., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318260de8b · Cited by 155
Self-citation
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
Akamatsu, H., Ninomiya, K., Kenmotsu, H., Morise, M., Daga, H., Goto, Y., Kozuki, T., Miura, S., Sasaki, T., Tamiya, A., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01431-z · Cited by 149
Self-citation
Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
Paz-Ares, L. G., Soulières, D., Melezínek, I., Moecks, J., Keil, L., Mok, T. S. K., Rosell, R., & Klughammer, B. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00991.x · Cited by 141
Novel Therapeutic Targets in Non-small Cell Lung Cancer
Jankú, F., Garrido‐Laguna, I., Petruzelka, L. B., Stewart, D. J., & Kurzrock, R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822944b3 · Cited by 133
Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer
Togashi, Y., Masago, K., Fukudo, M., Terada, T., Fujita, S., Irisa, K., Sakamori, Y., Kim, Y. H., Mio, T., Inui, K., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e2138b · Cited by 130
The Evolution of Therapies in Non-Small Cell Lung Cancer
Boolell, V., Alamgeer, M., Watkins, D. N., & Ganju, V. (2015) · Cancers · doi:10.3390/cancers7030864 · Cited by 130
Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology
McDermott, U., & Settleman, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9054 · Cited by 131
Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group
Umemura, S., Tsubouchi, K., Yoshioka, H., Hotta, K., Takigawa, N., Fujiwara, K., Horita, N., Segawa, Y., Hamada, N., Takata, I., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.03.002 · Cited by 122
Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy
Jin, J., Wu, X., Yin, J., Li, M., Shen, J., Li, J., Zhao, Y., Zhao, Q., Wu, J., Wen, Q., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00263 · Cited by 126
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients
Roengvoraphoj, M., Tsongalis, G. J., Dragnev, K. H., & Rigas, J. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.001 · Cited by 121
Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
Alam, M., Alam, S., Shamsi, A., Adnan, M., Elasbali, A. M., Al‐Soud, W. A., Alreshidi, M. M., Hawsawi, Y. M., Tippana, A., Pasupuleti, V. R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869672 · Cited by 122
LIV-1 Promotes Prostate Cancer Epithelial-to-Mesenchymal Transition and Metastasis through HB-EGF Shedding and EGFR-Mediated ERK Signaling
Lue, H.-W., Yang, X., Wang, R., Qian, W., Xu, R. Z. H., Lyles, R. H., Osunkoya, A. O., Zhou, B. P., Vessella, R. L., Zayzafoon, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027720 · Cited by 112
Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
Kobayashi, K., & Hagiwara, K. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0258-9 · Cited by 110
Self-citation
Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
Oya, Y., Yoshida, T., Kuroda, H., Mikubo, M., Kondo, C., Shimizu, J., Horio, Y., Sakao, Y., Hida, T., & Yatabe, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21602 · Cited by 109
Lung cancer in never smokers: Change of a mindset in the molecular era
Lee, Y. J., Kim, J.-H., Kim, S. I., Ha, S., Mok, T. S. K., Mitsudomi, T., & Cho, B. C. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.12.013 · Cited by 107
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
Nishie, K., Kawaguchi, T., Tamiya, A., Mimori, T., Takeuchi, N., Matsuda, Y., Omachi, N., Asami, K., Okishio, K., Atagi, S., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826913f7 · Cited by 104
Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?
Mok, T., Yang, J.-J., & Lam, K.-C. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0652 · Cited by 103
Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial
Oizumi, S., Kobayashi, K., Inoue, A., Maemondo, M., Sugawara, S., Yoshizawa, H., Isobe, H., Harada, M., Kinoshita, I., Okinaga, S., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0426 · Cited by 101
Self-citation
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients
Suh, C. H., Park, H. S., Kim, K. W., Pyo, J., Hatabu, H., & Nishino, M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.032 · Cited by 97
Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review
Köhler, J., & Schüler, M. (2013) · Oncology Research and Treatment · doi:10.1159/000354627 · Cited by 93
Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma
Murakami, S., Ito, H., Tsubokawa, N., Mimae, T., Sasada, S., Yoshiya, T., Miyata, Y., Yokose, T., Okada, M., & Nakayama, H. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.022 · Cited by 91
Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors
Giaccone, G., & Wang, Y. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.01.003 · Cited by 94
Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma
Shimizu (2011) · Oncology Reports · doi:10.3892/or.2011.1182 · Cited by 88
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
Cadranel, J. L., Ruppert, A.-M., Beau‐Faller, M., & Wislez, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.009 · Cited by 83
Novel therapeutic targets in non-small cell lung cancer
Alamgeer, M., Ganju, V., & Watkins, D. N. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.03.010 · Cited by 84
Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer
Kim, H. J., Lee, K. Y., Kim, Y., Kim, K. S., Lee, S. Y., Jang, T. W., Lee, M. K., Shin, K. C., Lee, G. H., Lee, J. C., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.08.005 · Cited by 75
Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States
Enewold, L., & Thomas, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156728 · Cited by 78
Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes
Lozano, M. D., Zulueta, J. J., Echeveste, J. I., Gúrpide, A., Seijo, L. M., Martín‐Algarra, S., del Barrio, A., Pı́o, R., Idoate, M. A., Labiano, T., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0155 · Cited by 74
Personalized Targeted Therapy for Lung Cancer
Wu, K., House, L. K., Liu, W., & Cho, W. C. S. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130911471 · Cited by 71
Gefitinib: a review of its use in adults with advanced non-small cell lung cancer
Dhillon, S. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0358-9 · Cited by 68
The “Lazarus Response” in Treatment-Naïve, Poor Performance Status Patients With Non–Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation
Langer, C. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4859 · Cited by 68
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3
Jaiyesimi, I. A., Leighl, N. B., Ismaila, N., Alluri, K. C., Florez, N., Gadgeel, S. M., Masters, G. A., Schenk, E. L., Schneider, B. J., Sequist, L. V. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02744 · Cited by 64
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
Doebele, R. C., Oton, A. B., Peled, N., Camidge, D. R., & Bunn, P. A. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.12.009 · Cited by 62
Gefitinib
Sanford, M., & Scott, L. J. (2009) · Drugs · doi:10.2165/10489100-000000000-00000 · Cited by 60
Scientific Challenges and Implementation Barriers to Translation of Pharmacogenomics in Clinical Practice
Lam, Y. W. F. (2013) · ISRN Pharmacology · doi:10.1155/2013/641089 · Cited by 61
Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer
Nakamura, S., Hayashi, K., Imaoka, Y., Kitamura, Y., Akazawa, Y., Tabata, K., de Groen, R. A. L., Tsuchiya, T., Yamasaki, N., Nagayasu, T., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186192 · Cited by 60
Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
Chang, Y. S., Choi, C., & Lee, J. C. (2016) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2016.79.4.248 · Cited by 59
Chemotherapy for advanced non-small cell lung cancer in the elderly population
Santos, F. N., Castria, T. B. D., Cruz, M. R., & Riera, R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010463.pub2 · Cited by 56
Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
Araki, T., Yashima, H., Shimizu, K., Aomori, T., Hashita, T., Kaira, K., Nakamura, T., & Yamamoto, K. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7340 · Cited by 59
Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
Dienstmann, R., Martínez, P., & Felip, E. (2011) · Oncotarget · doi:10.18632/oncotarget.245 · Cited by 54
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
Tiseo, M. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6594 · Cited by 51
Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)
Iwama, E., Goto, Y., Murakami, H., Harada, T., Tsumura, S., Sakashita, H., Mori, Y., Nakagaki, N., Fujita, Y., Seike, M., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.02.012 · Cited by 52
Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation–Positive Non–Small Cell Lung Cancer
Miyamoto, S., Azuma, K., Ishii, H., Bessho, A., Hosokawa, S., Fukamatsu, N., Kunitoh, H., Ishii, M., Tanaka, H., Aono, H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1250 · Cited by 51
Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Lung Adenocarcinoma: Results of a Nagano Lung Cancer Research Group Study
Asami, K., Koizumi, T., Hirai, K., Ameshima, S., Tsukadaira, A., Morozumi, N., Morikawa, A., Atagi, S., & Kawahara, M. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.02.004 · Cited by 49
A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer
Weickhardt, A. J., Doebele, R. C., Oton, A. B., Lettieri, J., Maxson, D. A., Reynolds, M., Brown, A., Jackson, M. K., Dy, G. K., Adjei, A. A., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823c5b11 · Cited by 49
RNA is favourable for analysingEGFRmutations in malignant pleural effusion of lung cancer
Tsai, T.-H., Su, K., Wu, S., Chang, Y., Luo, S., Jan, I., Yu, C., Yu, S.-L., Shih, J.-Y., & Yang, P. (2011) · European Respiratory Journal · doi:10.1183/09031936.00043511 · Cited by 50
Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors
Kato, Y. X., Hosomi, Y., Watanabe, K., Yomota, M., Kawai, S., Okuma, Y., Kubota, K., Seike, M., Gemma, A., & Okamura, T. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.06.03 · Cited by 49
Self-citation
Chemotherapy for lung cancer: the state of the art in 2009
Higgins, M. J., & Ettinger, D. S. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.115 · Cited by 49
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues
Gridelli, C., de Marinis, F., Maïo, M. D., Cortinovis, D. L., Cappuzzo, F., & Mok, T. S. K. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.12.009 · Cited by 48
Targeted therapy and elderly people: A review
Daste, A., Chakiba, C., Domblides, C., Gross‐Goupil, M., Quivy, A., Ravaud, A., & Soubeyran, P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.005 · Cited by 47
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer
Rosell, R., Viteri, S., Molina‐Vila, M. Á., Benlloch, S., & Tarón, M. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833500d2 · Cited by 45
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
Metro, G., & Crinò, L. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.34 · Cited by 45
The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer
Kwak, E. L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0087 · Cited by 44
M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma
Zhang, B., Zhang, Y., Zhao, J., Wang, Z., Wu, T., Ou, W., Wang, J., Yang, B., Zhao, Y. X., Rao, Z., et al. (2014) · Medical Oncology · doi:10.1007/s12032-014-0127-0 · Cited by 45
Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies
de Mello, R. A. (2011) · World Journal of Clinical Oncology · doi:10.5306/wjco.v2.i11.367 · Cited by 43
Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications
Juan, Ó., & Popat, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016687262 · Cited by 43
Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing
Murakami, S., Yokose, T., Nemoto, D., Suzuki, M., Usui, R., Nakahara, Y., Kondo, T., Kato, T., & Saito, H. (2021) · Diagnostics · doi:10.3390/diagnostics11030391 · Cited by 43
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)
Morère, J., Bréchot, J.-M., Westeel, V., Gounant, V., Lebeau, B., Vaylet, F., Barlési, F., Urban, T., Souquet, P.-J., Debieuvre, D., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.03.003 · Cited by 42
Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non‐small cell lung cancer
Hagiwara, K., & Kobayashi, K. (2012) · Cancer Science · doi:10.1111/cas.12081 · Cited by 42
Self-citation
Improving Molecular Testing and Personalized Medicine in Non-Small-Cell Lung Cancer in Ontario
Lim, C., Sekhon, H. S., Cutz, J.-C., Hwang, D., Kamel‐Reid, S., Carter, R., Santos, G. D. C., Waddell, T. K., Binnie, M., Patel, M., et al. (2017) · Current Oncology · doi:10.3747/co.24.3495 · Cited by 42
A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC
Carmichael, J. A., Mak, D. W.-S., & O’Brien, M. (2018) · Cancers · doi:10.3390/cancers10070236 · Cited by 42
A growing family: Adding mutated Erbb4 as a novel cancer target
Rudloff, U., & Samuels, Y. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11239 · Cited by 40
Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases
Fan, Y., Xu, Y., Gong, L., Fang, L., Lu, H., Qin, J., Han, N., Xie, F., Qiu, G., & Huang, Z. (2017) · Scientific Reports · doi:10.1038/srep45193 · Cited by 40
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations
Ludovini, V., Bianconi, F., Pistola, L., Minotti, V., Chiari, R., Colella, R., Bellezza, G., Tofanetti, F. R., Siggillino, A., Baldelli, E., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1829-7 · Cited by 39

Authors: Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., Ando, M., Yamazaki, K., Saijo, Y., Gemma, A., Miyazawa, H., Tanaka, T., Ikebuchi, K., Nukiwa, T., Morita, S., & Hagiwara, K.
Affiliations: Tohoku University (JP)
ORCID: Inoue, Akira
Kobayashi, Kunihiko
Usui, Kazuhiro
Maemondo, Makoto
Saijo, Yasuo
Gemma, Akihiko
Miyazawa, Hitoshi
Tanaka, Tomoaki
Ikebuchi, Kenji
Nukiwa, Toshihiro
Morita, Satoshi
Hagiwara, Koichi
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-03-20
Volume: 27
Issue: 9
Pages: 1394-1400
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2008.18.7658
OpenAlex: W2111191667
Cited by: 505
References: 32
Citations by year: 2026: 2 · 2025: 6 · 2024: 10 · 2023: 18 · 2022: 22 · 2021: 33 · 2020: 25 · 2019: 22 · 2018: 29 · 2017: 35 · 2016: 34 · 2015: 31 · 2014: 30 · 2013: 43 · 2012: 41
FWCI: 45.89
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: gefitinib, advanced non-small cell lung cancer, EGFR mutation, first-line therapy, poor performance status, chemotherapy-naive patients, EGFR mutation testing, overall response rate, progression-free survival, best supportive care
MeSH terms: Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Middle Aged, Mutation, Prospective Studies, Young Adult, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks